Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus

CITEDBY Reports

  1. Emma Gbandi, Antonis Goulas, Vassilios Sevastianos, Stephanos Hadziyannis, Athanasia Panderi, John Koskinas, George Papatheodoridis, Themistoklis Vasiliadis, Dimitrios Agapakis, Andreas Protopapas, Panagiota Ioannidou, George Zacharakis, Emmanuil Sinakos, Sotiris Koutsounas, Georgios Germanidis, . Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacological Reports, 2016; 68(2): 476.
    Crossref
  2. Minzhi Li, Jinjing Tan, Xiaoqing Yang, Li Su, Juanjuan Xie, Baoyun Liang, Jianxiong Long, Haiyun Jiang, Qiugui Wei, Tingting Shen, Qing Chen, Yan Yan, Guangliang Wu, Lian Gu, . The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy Research, 2014; 108(6): 1052.
    Crossref
  3. Mahamadou Tandia, Asma Mhiri, Bernard Paule, Raphaël Saffroy, Valérie Cailliez, Gaëlle Noé, Robert Farinotti, Laurence Bonhomme-Faivre, . Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemotherapy and Pharmacology, 2017; 79(4): 759.
    Crossref